TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04763304

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gown personal protective equipment (PPE-G) suit
Description: Placement of PPE-G under direct instructions (audio recording), fluorescent solution full-body spray, removal of PPE under direct instructions (audio recording) and assessment of self-contamination through ultraviolet light scanning. Active (wet wipe cleanse of any fluorescent traces visible under ultraviolet light scanning) and passive (15 minute interval) washout period to prevent a carry over effect on the second allocated intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gown personal protective equipment (PPE-G) suit
Description: Placement of PPE-G under direct instructions (audio recording), fluorescent solution full-body spray, removal of PPE under direct instructions (audio recording) and assessment of self-contamination through ultraviolet light scanning. Active (wet wipe cleanse of any fluorescent traces visible under ultraviolet light scanning) and passive (15 minute interval) washout period to prevent a carry over effect on the second allocated intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coverall personal protective equipment (PPE-C) suit
Description: Placement of PPE-C under direct instructions (audio recording), fluorescent solution full-body spray, removal of PPE under direct instructions (audio recording) and assessment of self-contamination through ultraviolet light scanning. Active (wet wipe cleanse of any fluorescent traces visible under ultraviolet light scanning) and passive (15 minute interval) washout period to prevent a carry over effect on the second allocated intervention.
Study: NCT02758561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workshop
Description: The first 15 minutes will be an information session on either Urinary Incontinence (UI) or Pelvic Organ Prolapse (PO) led by a Nurse Continence Advisor.~The following 60 minutes will comprise a psychologist-led group discussion. The structured discussion will encourage participants to share experiences, thoughts, and feelings on pelvic floor disorders. Resistances and barriers to seeking treatment will be discussed. Decision-making processes will be explored.~During the final 15 minutes, participants will be asked to complete a survey to evaluate the workshop. The survey will assess satisfaction with the information provided, quality of group discussion, comfort level with the group experience, and their satisfaction with the roles of the nurse continence advisor and psychologist.
Study: NCT01942395

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DASH/sodium-restricted diet (DASH/SRD)
Description: Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. The target sodium content will be 1,500 mg/2,100 kcal, as per recent American Heart Association population recommendations for sodium intake. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the 21 days urinary sodium, potassium, and 8-isoprostanes will again be measured.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DASH/sodium-restricted diet (DASH/SRD)
Description: Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. The target sodium content will be 1,500 mg/2,100 kcal, as per recent American Heart Association population recommendations for sodium intake. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the 21 days urinary sodium, potassium, and 8-isoprostanes will again be measured.
Study: NCT04763304

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coverall personal protective equipment (PPE-C) suit
Description: Placement of PPE-C under direct instructions (audio recording), fluorescent solution full-body spray, removal of PPE under direct instructions (audio recording) and assessment of self-contamination through ultraviolet light scanning. Active (wet wipe cleanse of any fluorescent traces visible under ultraviolet light scanning) and passive (15 minute interval) washout period to prevent a carry over effect on the second allocated intervention.
Study: NCT01526798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theralite (high cut-off hemodialysis)
Description: Hemodialysis with Theralite dialyzer alternating with standard high-flux dialyzer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional high-flux dialyzer
Study: NCT00599924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib + FOLFOX
Description: 37.5 mg sunitinib + modified FOLFOX6 (Schedule 2/2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib + FOLFOX
Description: 50 mg sunitinib + modified FOLFOX6 (Schedule 2/2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib + FOLFOX
Description: 50 mg sunitinib + modified FOLFOX6 ( CRC, only Schedule 2/2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib + FOLFOX
Description: 37.5 mg sunitinib + modified FOLFOX6 (Schedule 4/2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib + FOLFOX
Description: 50 mg sunitinib + modified FOLFOX6 (Schedule 4/2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib + FOLFOX
Description: 37.5 mg sunitinib + modified FOLFOX6 (Continuous Dosing)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib + FOLFOX
Description: 25 mg sunitinib + modified FOLFOX6 (Continuous Dosing)
Study: NCT02936570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987521
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z09-067)
Study: NCT04773483

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Quorn Foods products
Description: 180 g mycoprotein (wet weight; corresponding to 45 g dry weight) per day (equates to approx. 215 g Quorn Foods products, depending on the product)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Meat/fish products
Description: Standard meat/fish products matched to Quorn group for protein intake
Study: NCT01942395

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Diet
Description: The Control Diet will be patterned on the information we collected using Food Frequency Questionnaires during our pilot study HUM00025253 (i.e., the dietary patterns reported by previously recruited hypertensive HFPEF patients). The target sodium content will be 3,500 mg per 2,100 kcal and target potassium content for the control diet will be 2,000 mg per 2,100 kcal.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Diet
Description: The Control Diet will be patterned on the information we collected using Food Frequency Questionnaires during our pilot study HUM00025253 (i.e., the dietary patterns reported by previously recruited hypertensive HFPEF patients). The target sodium content will be 3,500 mg per 2,100 kcal and target potassium content for the control diet will be 2,000 mg per 2,100 kcal.
Study: NCT04591704

Intervention type: OTHER
Intervention: hospitalisation, necessity of ICU, mortality rate, lung involvement
Description: hospitalisation, necessity of ICU, mortality rate, lung involvement
Study: NCT02255604

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.
Description: 4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.
Description: 3 injection into a lymphnode

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 0.1 ml Isoton saline
Description: 4 injection into a lymphnode
Study: NCT02534870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: Tablet
Study: NCT02638545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Sedation with propofol and remifentanyl will be replaced by a sedation with dexmedetomidine and remifentanyl
Study: NCT05954013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PD_Pal intervention
Description: The PD_Pal intervention will be delivered by a nurse that is specifically trained to deliver the PD_Pal intervention, i.e. the PD_Pal nurse. In the PD_Pal intervention, the patient, family caregiver and PD_Pal nurse complete four steps wherein they discuss and compose a: 1) Individual care plan; 2) Proactive care plan; 3) Quality of life and end-of-life plan and; 4) Coordination and revision plan. Together these steps lead to the Parkinson Support Plan. To facilitate patients in taking these steps, all patients receive a Parkinson Support Plan workbook. This workbook consists of information and questions aligned with the four steps. Patients can utilize this workbook before, during, or after the conversations with the PD_Pal nurse.
Study: NCT03808545

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention for Physical Activity in Multiple Sclerosis (BIPAMS)
Description: This is a newly developed Internet website that delivered a Social Cognitive Theory-based behavioral intervention using e-learning and one-on-one video chats approaches for increasing physical activity and improving symptoms, walking impairment, and neurological disability. The intervention will last 16 weeks and will include physical activity information.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BIPAMS + Diet
Description: For 8 weeks a participant will complete the standard BIPAMS intervention. For the subsequent 8 weeks, in addition to the BIPAMS website, participants will receive a diet prescription with instructions and guidance on their one-on-one video calls and will utilize the HealthWatch360 app and/or desktop website to track their dietary intake. The total intervention will last 16 weeks and will include physical activity information and dietary information.
Study: NCT00517998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biologic Lung Volume Reduction (BLVR) - 10 mL Hydrogel
Description: 10 mL Hydrogel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biologic Lung Volume Reduction (BLVR) - 10 mL Hydrogel
Description: 10 mL Hydrogel
Study: NCT02531906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03229278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzyme Inhibitor Therapy
Description: Given trigriluzole PO
Study: NCT03327792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavoglurant
Description: 200 mg Mavoglurant
Study: NCT03229278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT04271137

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: 3D printed PEEK onlay
Description: 3d computer-designed Orbital onlay

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Pre-bent orbital mesh
Description: Pre-bent orbital mesh on 3d printed template
Study: NCT03474913

Intervention type: DEVICE
Intervention: Upright MRI
Description: Indomitable Magnetic Resonance Imaging Scanner, magnetic resonance imaging using 0.6 T strength

Intervention type: DEVICE
Intervention: Upright MRI
Description: Indomitable Magnetic Resonance Imaging Scanner, magnetic resonance imaging using 0.6 T strength
Study: NCT01171976

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab (Lucentis®) was supplied in vials containing a dose of 0.5 mg/0.05 mL in an aqueous solution (pH 5.5) with histidine, trehalose, and polysorbate 20.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab (Lucentis®) was supplied in vials containing a dose of 0.5 mg/0.05 mL in an aqueous solution (pH 5.5) with histidine, trehalose, and polysorbate 20.
Study: NCT03474913

Intervention type: DEVICE
Intervention: Standard MRI
Description: standard of care closed 3T MRI
Study: NCT02456753

Intervention type: DEVICE
Intervention: trans-perineal ultrasonography
Description: Assesment of the fetal head-perineum distance via a trans-perineal ultrasonography
Study: NCT06421714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venglustat
Description: Pharmaceutical form:Capsule-Route of administration:Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Pharmaceutical form:Capsule-Route of administration:Oral
Study: NCT05175131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebeverine+Simethicone
Description: fixed-dose combination, film-coated tablets, 135 mg + 80 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mebeverine
Description: Duspatalin®, coated tablets 135 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simethicone
Description: Espumisan® capsules 40 mg
Study: NCT02858440

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/Hib
Description: Subjects receive Infanrix-IPV/Hib three-dose primary vaccination course at 3, 4.5 and 6 months of age and a booster dose at 18 months of age. The vaccine is administered intramuscularly into the upper side of the thigh on the right/left side.
Study: NCT01171976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab (Lucentis®) was supplied in vials containing a dose of 0.5 mg/0.05 mL in an aqueous solution (pH 5.5) with histidine, trehalose, and polysorbate 20.
Study: NCT01140867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zonisamide
Description: zonisamide 100 mg tablet
Study: NCT03617536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR845 0.25 mg Oral Tablet
Description: CR845 0.25 mg medication taken orally 1 time/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR845 0.5 mg Oral Tablet
Description: CR845 0.5 mg medication taken orally 1 time/day
Study: NCT02958800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention will be 12-weeks in duration consisting of four blocks resulting from a 1:1 randomization of two different three-week treatment courses of a patient's existing antipsychotic medication. For example, the intervention ABAB means that a participant would undergo three weeks of treatment A, followed by three weeks of treatment B, followed by three weeks of treatment A, and lastly three weeks of treatment B.~Treatment A block is defined as a mutually agreed upon dose of a participant's antipsychotic medication that is different (i.e. lower) than their enrolment dose.~Treatment B block is defined as a mutually agreed upon dose of a participant's antipsychotic medication that is different (i.e. lower) than their enrolment dose and the dose in Treatment A.
Study: NCT00940069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 'TS high expression genotype': pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of each 21 day,for not less than 4 cycle, administered intravenously every 3 weeks.~'TS low expression genotype': pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of each 21 day,for not less than 4 cycle, administered intravenously every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 'TS high expression genotype': pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of each 21 day,for not less than 4 cycle, administered intravenously every 3 weeks.~'TS low expression genotype': pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of each 21 day,for not less than 4 cycle, administered intravenously every 3 weeks.
Study: NCT04030585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot
Description: Patients with upper limb amputation using myoelectric prosthesis will done robot-assisted exercise program
Study: NCT03327792

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04030585

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise
Description: Patients with upper limb amputation using myoelectric prosthesis will done home exercise program
Study: NCT03067948

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Designated Positive Screen Shared with Provider
Description: Patient Designated Positive Screen Shared with Provider -- In the intervention, participants will be given the opportunity to determine which positive screen, if any, that the participant would like to discuss with the participant's provider at the next HIV primary care appointment. The participant will be notified that all positive screens will be shared with the provider prior to their next HIV primary care visit, and that any positive screen the patient has chosen to discuss with the provider will be specified. The provider will receive the PROs result (score, interpretation, and recommendation) prior to their next HIV primary care visit
Study: NCT04000516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted feeding
Description: Restricting the eating window to about 8 hours a day, during waking hours.
Study: NCT01796912

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lipoprotein Apheresis
Description: Weekly lipoprotein apheresis for 3 months

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Apheresis
Description: Weekly sham (placebo) apheresis for 3 months
Study: NCT00951496

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03908060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: One intravenous administration of methadone (0.2 mg/kg ideal body weight)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: One intravenous administration of morphine (0.2 mg/kg ideal body weight)
Study: NCT04027439

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Part A: RPL554
Description: 1 dose of either 50mcg/100mcg/1500mcg/3000mcg/6000mcg or placebo via dry powder inhaler
Study: NCT03617536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR845 1 mg Oral Tablet
Description: CR845 1 mg medication taken orally 1 time/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablet taken orally 1 time/day
Study: NCT02429193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone + prednisone
Description: Abiraterone acetate (1000 mg/day p.o.) + prednisone (5 mg b.i.d., p.o.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide (160 mg/day p.o.)
Study: NCT02325570

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KLOX BioPhotonic OraLum Gel
Description: Klox BioPhotonic OraLum Gel will be used with a LED curing lamp as an adjunct to conventional non-surgical periodontal treatment (SRP).
Study: NCT03602638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 100mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: Acarbose
Study: NCT02482389

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single fraction of 7 Gy
Description: All subjects will receive a single 7 Gy fraction of radiotherapy to the intact tumor prior to surgery.
Study: NCT00407420

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mandometer
Description: A computerised device, Mandometer, providing real time feedback to participants during meals to slow down speed of eating and reduce total intake; standard lifestyle modification therapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandometer
Description: A computerised device, Mandometer, providing real time feedback to participants during meals to slow down speed of eating and reduce total intake; standard lifestyle modification therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle
Description: Typical dietary and activity advice as normally provided in clinic (control).
Study: NCT00879788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril 10mg capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril 10mg capsules